This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Wadi N. Suki, MD

Arch Intern Med. 1989;149(3):669-673.

Abstract
• Angiotensin-converting enzyme (ACE) inhibitors are of benefit in the management of heart failure. In some studies in patients with heart failure, a decline in renal function occurred more frequently in patients treated with enalapril maleate, a longer-acting agent, than in those treated with captopril, a shorter-acting drug. Patients experiencing a decline in renal function had a number of predisposing hormonal and hemodynamic factors. In one report, these factors included an initial fall in blood pressure that was sustained, lower cardiac output, and a relatively high fixed dose of enalapril that contributed to renal impairment. In a second study, the decline in renal function was most severe in patients with a lower systemic arterial pressure in whom glomerular filtration may have been dependent on angiotensin II. In a third study, intravascular volume depletion and an activated renin-angiotensin system led to reduced renal function. Reduction of angiotensin II level in plasma and tissues by ACE inhibitors decreases systemic vascular resistance and efferent arteriolar tone, which tends to decrease glomerular filtration rate. If compensatory increases in cardiac output are inadequate or preexisting renal impairment or volume depletion is present, renal function will deteriorate. Long-acting ACE inhibitors prolong the decreased efferent arteriolar tone and may compromise cardiac muscle response to catecholamines. The use of shorter-acting agents in patients who exhibit deterioration in renal function may be preferable.

(Arch Intern Med 1989;149:669-673)

Author Affiliations
From the Department of Medicine, Baylor College of Medicine and Methodist Hospital, Houston.

Footnotes
Accepted for publication Oct 26, 1988.

Reprint requests to the Renal Section, Smith Tower, 6550 Fannin, Suite 1273, Houston, TX 77030 (Dr Suki).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Blood Urea Nitrogen and Serum Creatinine: Not Married in Heart Failure
Schrier
Circ Heart Fail 2008;1:2-5.
FULL TEXT  

Role of Diminished Renal Function in Cardiovascular Mortality: Marker or Pathogenetic Factor?
Schrier
J Am Coll Cardiol 2006;47:1-8.
ABSTRACT | FULL TEXT  

Acute Renal Failure and Sepsis
Bellomo et al.
NEJM 2004;351:2347-2349.
FULL TEXT  

Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy: A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association
Schoolwerth et al.
Circulation 2001;104:1985-1991.
FULL TEXT  

Hormones and Hemodynamics in Heart Failure
Schrier and Abraham
NEJM 1999;341:577-585.
FULL TEXT  

Management of Heart Failure: I. Pharmacologic Treatment
Baker et al.
JAMA 1994;272:1361-1366.
ABSTRACT  

Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors
Oster and Materson
Arch Intern Med 1992;152:704-710.
ABSTRACT  

Reversible Renal Failure Associated with Angiotensin-Converting Enzyme Inhibitors in Polycystic Kidney Disease
Chapman et al.
ANN INTERN MED 1991;115:769-773.
ABSTRACT  

Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure
Munger et al.
Journal of Pharmacy Practice 1990;3:318-331.
ABSTRACT